Nov 12,2021

OncoHost to Present Data at SITC 2021 on Predicting NSCLC Patient Response to Immunotherapy Utilizing Proteomic Profiling

OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has published a study identifying three distinct proteome subtypes that are associated with response from a cohort of non-small cell lung cancer (NSCLC) patients undergoing immunotherapy.

CLINICAL STUDY

#platform

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 30,2021

Rewriting the Oncology Patient’s Journey with Real-World Data

Improved collaboration and communication between patients, industry, and clinicians will be key for smoothing out the bumps in an oncology patient’s journey, said a panel of life science leaders in a recent COTA webinar.

View Analyst & Ambassador Comments
Go to original news
Nov 30,2021

COTA Collaborates with University of Chicago Medicine and UT Southwestern on Research To Be Presented at the American Society for Hematology’s Annual Meeting & Exposition

COTA, Inc., an oncology real-world data and analytics company, today announced four of their abstracts will be showcased at the American Society for Hematology’s (ASH) Annual Meeting & Exposition from December 11–14, 2021, in Atlanta, Georgia. COTA has the most comprehensive hematology oncology real-world data that is curated under the close guidance of leading oncologists and hematology specialists.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 08,2021

Vinehealth, offering digital support for cancer patients and SaaS for R&D, gets $5.5M to launch in the US

Vinehealth has raised $5.5 million of investment in our latest seed funding round, led by Talis Capital with participation from previous investors Playfair Capital and Ascension, as well as a number of angel investors. The Compayn said that this investment builds on their CE mark which was achieved in record time earlier this year; a significant regulatory milestone and will help them to further develop their product, scale their team and expand in the US.

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Dec 06,2021

Transitioning from Reactive to Proactive cancer care based on robust, evidence-based histopathology diagnosis

Karkinos Healthcare is dedicated to delivering the 4Ds, which are Detection, Diagnosis, Delivery, and Data. All of these services rely on pathology with the stream of medicine providing a good complementary role in the cancer journey of any patient. To prevent recurrence of cancer or spread to other organs of the body, the company’s patient navigation system includes an effective follow-up and surveillance plan for the patient. And in each of this service offering, pathology finds itself playing a significant part. Karkinos Healthcare claims to forefront cancer care employing enhanced digital histopathology. Pathologists here will use digital imaging modalities to do diagnostic and quantitative analysis. Automated image analysis using AI and ML will be Karkinos Healthcare forte

PRODUCT

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Dec 14,2021

Building a data-powered oncology ecosystem for connected care continuum

Dr. Anjali Kulkarni, VP Clinical Informatics, Karkinos Healthcare explains how the company is improving cancer care in India with digitally enabled tools and services.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 14,2021

One year of partnership between Tübingen University Hospital and Kaiku Health

Kaiku Health helps the clinical staff at Tübingen gather more information on patients’ conditions and experiences during and after care. The platform automatically notifies the care teams, if a patient’s symptoms worsen during the treatment course. This helps the clinical staff be better informed and provide quality care where it is most urgently needed. In addition to the AI-powered monitoring of patients’ symptoms and patient-reported outcomes, Kaiku Health connects patients with the care teams and provides timely support and guidance throughout the treatment pathway. This personalised support further helps to improve the quality of life for patients

COLLABORATION PARTNERSHIP

#institution

#rpm

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 01,2021

Protocol First Joins Flatiron Health

Protocol First, a software solutions provider focused on accelerating clinical research, has joined Flatiron HealthⓇ as a wholly owned subsidiary, the two companies announced today. “This is a win-win for both companies,” said Carolyn Starrett, Flatiron CEO. “Flatiron and Protocol First share a common vision in which technology and software increasingly bridge the gap between real-world care and clinical research.”

COLLABORATION MERGERS & ACQUISITION

#data & technology

#platform

View Analyst & Ambassador Comments
Go to original news
Dec 09,2021

Massive Bio Launches the 100K Cancer Clinical Trial Singularity Program

Massive Bio, a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric clinical trial enrollment for oncology announced the launch of its 100K CANCER CLINICAL TRIAL SINGULARITY PROGRAM, a first-of-its-kind program aimed to provide real-time access to cutting-edge clinical trials for cancer patients globally.

View Analyst & Ambassador Comments
Go to original news
Dec 10,2021

Health App Tracks Disease Symptoms, Medications, Side Effects, More – Newsmax Health

There’s an exciting health app that you can download for free that helps monitor your symptoms, keep track of medications, and identify side effects for a wide variety of medical conditions including cancer, chronic pain, migraines, and even anxiety and depression. Called Wave Health, it is available for both iPhone and Android devices. The mobile app was rated #1 by Cedars Sinai Hospital for tracking patient-reported outcomes, or PROs, for oncology patients.

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY